Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 01, 2022 07:30 ET | Source: Adaptive Biotechnologies

Adaptive Biotechnologies Announces Launch of clonoSEQ® to Assess Minimal Residual Disease (MRD) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Using Circulating Tumor DNA (ctDNA)

clonoSEQ is the first and only MRD test in DLBCL with Medicare coverage across all lines of therapy, treatment regimens, and timepointsAdaptive now accepts blood samples from DLBCL patients in Streck®...
November 21, 2022 16:05 ET | Source: Adaptive Biotechnologies

Adaptive Biotechnologies to Participate in the Piper Sandler Healthcare Conference

SEATTLE, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
November 21, 2022 07:30 ET | Source: Adaptive Biotechnologies

New Survey Reveals the Majority of Myeloma Patients That Undergo Minimal Residual Disease (MRD) Testing Find a Clear Clinical or Emotional Benefit from Results

>95% of patients who had an MRD test describe that MRD testing helped inform treatment decisions or brought comfort in their treatment journey85% of surveyed patients have heard of MRD testing, yet...
November 03, 2022 16:05 ET | Source: Adaptive Biotechnologies

Adaptive Biotechnologies Reports Third Quarter 2022 Financial Results

SEATTLE, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
October 11, 2022 08:05 ET | Source: Adaptive Biotechnologies

Adaptive Announces Partnership with Epic to Increase Access to Minimal Residual Disease (MRD) Monitoring in Blood Cancers

SEATTLE, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
October 05, 2022 16:05 ET | Source: Adaptive Biotechnologies

Adaptive Biotechnologies to Report Third Quarter of 2022 Financial Results on November 3, 2022

SEATTLE, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that translates the genetics of the adaptive immune system...
September 12, 2022 08:30 ET | Source: Adaptive Biotechnologies

Adaptive Biotechnologies Announces Non-Dilutive Royalty Financing with OrbiMed for Up to $250 Million

SEATTLE, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that translates the genetics of the adaptive immune system...
September 02, 2022 08:00 ET | Source: Adaptive Biotechnologies

Adaptive Biotechnologies to Participate in the Morgan Stanley Global Healthcare Conference

SEATTLE, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
August 03, 2022 16:05 ET | Source: Adaptive Biotechnologies

Adaptive Biotechnologies Reports Second Quarter 2022 Financial Results

SEATTLE, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
July 28, 2022 07:30 ET | Source: Adaptive Biotechnologies

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Monitoring Minimal Residual Disease in Diffuse Large B-Cell Lymphoma

SEATTLE, July 28, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...